FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Silberstein Charles						2. Issuer Name and Ticker or Trading Symbol <u>Applied Therapeutics Inc.</u> [APLT]									k all app Direc	ionship of Reporti all applicable) Director Officer (give title		n(s) to Is 10% Ov Other (s	vner
						3. Date of Earliest Transaction (Month/Day/Year) 12/14/2021								X	below		ncial O	below)	
(Street) NEW YORK NY 10017 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) 12/16/2021								Line)	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	iciall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					Execution Date,						es Acquired (A) Of (D) (Instr. 3, 4		4 and Secur Benef		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(
Common Stock 12/14/20					2021				A		47,900(1)	A \$0.0		\$0.00	00 135,703		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)	Date Exercis	able	Expiration Date	Title	Numb of Share						

Explanation of Responses:

1. Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 14, 2022, and one-twelfth (1/12th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each quarter thereafter, subject to the Reporting Person continuing to provide services through each such date.

This amendment is being filed solely to correct the vesting schedule for the compensatory Restricted Stock Units reported on the Reporting Person's Form 4 filed on December 16, 2021.

/s/ Shoshana Shendelman as attorney-in-fact

01/11/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.